Ecopetrol
EC
Lennar Corp
LEN
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
Adobe
ADBE
US Stock MarketDetailed Quotes
ANEB Anebulo Pharmaceuticals
- 1.550
- -0.070-4.32%
Trading Dec 26 11:23 ET
63.68MMarket Cap-5.17P/E (TTM)
1.674High1.490Low9.04KVolume1.490Open1.620Pre Close13.91KTurnover0.05%Turnover RatioLossP/E (Static)41.08MShares3.30052wk High33.70P/B29.55MFloat Cap0.80052wk Low--Dividend TTM19.06MShs Float9.330Historical High--Div YieldTTM11.35%Amplitude0.800Historical Low1.539Avg Price1Lot Size
Anebulo Pharmaceuticals News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Anebulo Pharmaceuticals Collaborates With FDA to Advance Selonabant
Express News | Anebulo Pharmaceuticals: Intends to Modify Loan and Security Agreement by Reducing Maximum Loan Size to About $3 Mln
Express News | Anebulo Pharmaceuticals: Entered Stock Purchase Agreement for Issuance & Sale of 15.2 Mln Shares of Common Stock for $15 Mln
Anebulo Pharmaceuticals Announces FDA Feedback For IV Selonabant To Address Cannabis-Induced Toxicity In Children And Completes $15M Capital Raise; Phase I Study Planned For 1H25
Express News | Anebulo Pharmaceuticals Inc: Plans to Begin Its Phase I Sad Study of IV Selonabant in Healthy Adults in 1H25
Express News | Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Anebulo Pharmaceuticals | 10-Q: Q1 2025 Earnings Report
Anebulo Pharmaceuticals Q1 EPS $(0.08) Up From $(0.10) YoY
Anebulo Pharmaceuticals | 8-K: Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
Benchmark Co. Maintains Anebulo Pharmaceuticals(ANEB.US) With Buy Rating, Maintains Target Price $8
Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target
Anebulo Pharmaceuticals Analyst Ratings
Anebulo Pharmaceuticals | 10-K: FY2024 Annual Report
Anebulo Pharmaceuticals | 8-K: Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
Express News | Anebulo Pharmaceuticals, Inc. Q4 Operating Expenses USD 1.3 Million
Anebulo Pharmaceuticals 4Q Loss/Shr 5c >ANEB
Express News | Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
Top Premarket Decliners
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
